The World Health Organization (WHO) estimated that 490 000 cases of multidrug-resistant (MDR) tuberculosis (TB) (defined as TB caused by Mycobacterium tuberculosis strains resistant to at least isoniazid and rifampicin) occurred in 2016. Among them, ∼6.2% had extensively drug-resistant (XDR) TB ( i.e. TB caused by MDR strains with additional resistance to fluoroquinolones and at least one second-line injectable drug) [1]. Efficacy and safety of co-administered bedaquiline and delamanid in MDR-TB patients This paper is part of the European Respiratory Society (ERS)/Latin American Society of Respiratory Medicine (ALAT) and ERS/Brazilian Society of Pulmonology (SBPT) collaborative projects, and of the operational research plan of the WHO Collaborating Centre for Tuberculosis and Lung Diseases, Tradate, ITA-80, 2017-2020- GBM/RC/LDA.
No takes yet. Share an insight, caveat, or question.
Pontali et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: